&gt; Do these companies still charge the same prices as in the US?<p>The majority of global R&amp;D happens in the US market, even though the entire world benefits from it. So pharmaceutical companies have come to expect to recoup their R&amp;D costs from the US market. Ultimately, this means that European markets benefit from the research without having to shoulder the bulk of the costs from it.<p>If they couldn&#x27;t do that here, then yes, they might adjust their business models and try and charge more in Europe and India. But as mentioned above, India doesn&#x27;t recognize patents, and since the R&amp;D isn&#x27;t taking place in Europe, there&#x27;s less of a need to charge the same prices there. And because there isn&#x27;t one single European market, its more complicated to price drugs there in such a way as to reliably turn a profit (after accounting for R&amp;D) in each individual country than it is in the US, where insurance players are licensed by state but the pharmaceutical market is otherwise roughly uniform across all 50 states.